Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial. Bahlis NJ, Costello CL, Raje NS, Levy MY, et al. Nat Med 2023;29:2570-2576.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Bahlis NJ, Costello CL, Raje NS, Levy MY, et al. Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial. Nat Med 2023;29:2570-2576.
PMID: 37783970